Who is sponsoring NCT02993068?

NCT02993068 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02993068?

Interventions in NCT02993068: Educational Intervention, Genetic Counseling, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration.

What condition does NCT02993068 study?

NCT02993068 studies BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma.

Is NCT02993068 still recruiting?

NCT02993068 is currently suspended. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT02993068

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Suspended NA Last updated 19 February 2026

What this trial tests

NA trial testing Educational Intervention in BARD1 Gene Mutation in 5,200 participants. Suspended.

Timeline

18 April 2017

Primary endpoint
18 April 2026

18 April 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	5,200
Start date	18 April 2017
Primary completion	18 April 2026
Estimated completion	18 April 2026
Sites	2 locations across United States

Drugs / interventions tested

Educational Intervention
Genetic Counseling
Genetic Counseling
Laboratory Biomarker Analysis — full drug profile →
Questionnaire Administration

Conditions studied

BARD1 Gene Mutation — all drugs for BARD1 Gene Mutation →
BRCA1 Gene Mutation — all drugs for BRCA1 Gene Mutation →
BRCA2 Gene Mutation — all drugs for BRCA2 Gene Mutation →
BRIP1 Gene Mutation — all drugs for BRIP1 Gene Mutation →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

30 and older, female only, with BARD1 Gene Mutation or BRCA1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.
Swisher EM, Rayes N, Bowen D, Peterson CB, et al · · 2023 · cited 32× · PMID 37707822 · DOI 10.1001/jamaoncol.2023.3748
MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
Rayes N, Bowen DJ, Coffin T, Nebgen D, et al · · 2019 · cited 29× · PMID 31266460 · DOI 10.1186/s12885-019-5868-x
A novel system to provide information via online YouTube videos and an evaluation of current online information about hereditary breast cancer.
Iesato A, Fushimi A, Tahara R, Terada M, et al · · 2024 · cited 11× · PMID 37995024 · DOI 10.1007/s12282-023-01512-y
Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.
Coffin T, Bowen D, Lu K, Swisher EM, et al · · 2022 · cited 6× · PMID 36155347 · DOI 10.2196/35035
Rapidly Changing Landscape of Fallopian Tube Carcinoma.
Kurnit KC, Lu KH, Westin SN. · · 2019 · PMID 31283416 · DOI 10.1200/jop.19.00248

Verify or expand the search:

Other trials of Educational Intervention

Trials testing the same drug.

NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07490860 — A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to · NA · not yet recruiting
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting

Other recruiting trials for BARD1 Gene Mutation

Currently open trials in the same condition.

NCT05420064 — An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Inte · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02993068 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02993068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing